RESUMO
BACKGROUND AND OBJECTIVES: Ganglioside antibodies can help diagnose distinct acute and chronic inflammatory neuropathies including axonal variants of Guillain-Barre syndrome, Miller-Fisher syndrome (MFS), multifocal motor neuropathy, and chronic sensory ataxic neuropathies. Because ganglioside antibody testing may be routinely ordered in patients with suspected inflammatory neuropathy, we sought to evaluate its yield and utilization in clinical practice. METHODS: We performed a retrospective chart review of all patients at London Health Sciences Centre who underwent ganglioside antibody testing between April 2019 and August 2023. The disease phenotype was determined for each patient, and the proportion of all tests that yielded a true-positive result was calculated. Ganglioside antibody positivity was classified as a true-positive result if the disease phenotype was robustly associated with the detected ganglioside antibody and there was no other more likely diagnosis. RESULTS: We identified 92 patients who underwent ganglioside antibody testing. One patient (1%) was classified as having a true-positive result; this patient had GQ1b-IgG positivity with MFS. Among 92 patients tested, 20 patients (22%) had a disease phenotype that was considered to be robustly associated with ganglioside antibody positivity. CONCLUSIONS: The yield of ganglioside antibody testing in clinical practice is low. We found that this testing is frequently ordered in patients with disease phenotypes that are not robustly associated with ganglioside antibody positivity, indicating that suboptimal test utilization is a primary contributor to its low yield. Restricting ganglioside antibody testing to patients with characteristic disease phenotypes would be valuable to improving yield and utilization of this testing.
Assuntos
Síndrome de Guillain-Barré , Síndrome de Miller Fisher , Humanos , Gangliosídeos , Estudos Retrospectivos , Anticorpos , Síndrome de Guillain-Barré/diagnóstico , Síndrome de Miller Fisher/diagnóstico , Síndrome de Miller Fisher/complicações , AutoanticorposRESUMO
BACKGROUND: In accordance with the rising number of SARS-CoV2 infections, reports of neurological complications have also increased. They include cerebrovascular diseases but also immunological diseases such as Guillain-Barre syndrome (GBS), Miller-Fisher syndrome (MFS), and opsoclonus-myoclonus-ataxia syndrome (OMAS). While GBS and MFS are typical postinfectious complications, OMAS has only recently been described in the context of COVID-19. GBS, MFS, and OMAS can occur as para- and postinfectious, with different underlying pathomechanisms depending on the time of neurological symptom onset. The study aimed to describe clinical features, time between infection and onset of neurological symptoms, and outcome for these diseases. METHODS: All COVID-19 patients treated in the neurological ward between January 2020 and December 2022 were screened for GBS, MFS, and OMAS. The clinical features of all patients, with a particular focus on the time of onset of neurological symptoms, were analyzed. RESULTS: This case series included 12 patients (7 GBS, 2 MFS, 3 OMAS). All GBS and one MFS patient received immunomodulatory treatment. Three patients (2 GBS, 1 OMAS) had a severe COVID-19 infection and received mechanical ventilation. In patients with OMAS, only one patient received treatment with intravenous immunoglobulin and cortisone. The remaining two patients, both with disease onset concurrent with SARS-COV2 infection, recovered swiftly without treatment. In all subgroups, patients with concurrent onset of neurological symptoms and COVID-19 infection showed a trend toward shorter disease duration. CONCLUSION: All patient groups displayed a shorter disease duration if the onset of neurological symptoms occurred shortly after the COVID-19 diagnosis. In particular, both the OMAS patients with symptom onset concurrent with COVID-19 showed only abortive symptoms followed by a swift recovery. This observation would suggest different pathomechanisms for immune-mediated diseases depending on the time of onset after an infection.
Assuntos
COVID-19 , Síndrome de Guillain-Barré , Síndrome de Miller Fisher , Mioclonia , Transtornos da Motilidade Ocular , Humanos , Síndrome de Guillain-Barré/diagnóstico , Síndrome de Guillain-Barré/terapia , Síndrome de Guillain-Barré/complicações , Estudos Retrospectivos , Teste para COVID-19 , Mioclonia/complicações , Transtornos da Motilidade Ocular/complicações , COVID-19/complicações , SARS-CoV-2 , Síndrome de Miller Fisher/diagnóstico , Síndrome de Miller Fisher/terapia , Síndrome de Miller Fisher/complicações , Ataxia/complicaçõesRESUMO
Bickerstaff brainstem encephalitis (BBE) is a neuroimmunologic disease characterized by the acute onset of external ophthalmoplegia, ataxia, and consciousness disturbance, mostly subsequent to an infection. BBE is considered to be a variant of Miller-Fisher syndrome (MFS), which also exhibits external ophthalmoplegia and ataxia but not presenting consciousness alterations. Therefore, these two medical conditions are included in the clinical spectrum of the "Fisher-Bickerstaff syndrome" ( Shahrizaila and Yuki in J Neurol Neurosurg Psychiatry 84(5):576-583) [1]. With regard to the etiopathogenesis, increasing evidence worldwide suggests that SARS-CoV-2 infection-enhanced immune response is involved in a wide range of neurological complications such as Guillain-Barré syndrome (GBS), MFS, acute necrotizing encephalitis (ANE), myelitis, acute disseminated encephalomyelitis (ADEM), and, although very rarely, BBE either (Hosseini et al. in Rev Neurosci 32:671-691) [2]. We report a case of a patient affected by delayed onset BBE overlapping MFS during a mild SARS-CoV-2 infection. To the best of our knowledge, similar cases have never been reported.
Assuntos
COVID-19 , Encefalite , Oftalmopatias , Síndrome de Guillain-Barré , Síndrome de Miller Fisher , Oftalmoplegia , Humanos , Síndrome de Miller Fisher/complicações , Síndrome de Miller Fisher/diagnóstico , COVID-19/complicações , COVID-19/patologia , SARS-CoV-2 , Síndrome de Guillain-Barré/complicações , Síndrome de Guillain-Barré/diagnóstico , Encefalite/complicações , Encefalite/diagnóstico , Ataxia/complicações , Oftalmopatias/complicações , Tronco Encefálico/diagnóstico por imagem , Tronco Encefálico/patologiaRESUMO
Guillain-Barré syndrome (GBS) and Miller Fisher syndrome (MFS) are acute immune-mediated peripheral neuropathies. In addition to their classic presentations, a variety of other signs and symptoms have been reported; however, headache appears to be relatively uncommon. We describe a 53-year-old woman who presented with acute bulbar palsy as the first symptom of overlapping MFS/GBS accompanied by severe headache. The first important clinical impairment of the patient was acute bulbar palsy along with prominent headache, without limb weakness. Although her initial diagnosis was acute bulbar palsy plus, she subsequently developed lower limb diffuse weakness, and her final clinical diagnosis was overlapping MFS/GBS. Anti-ganglioside antibodies were positive for anti-GQ1b and anti-GT1a immunoglobulin G. The patient received intravenous immunoglobulin on day 2 of admission. Early identification of these overlapping syndromes is important for the management of patients, to avoid respiratory failure or severe weakness with axonal degeneration. We therefore remind clinicians of the importance of further examination in patients with headache and acute bulbar palsy of unknown origin.
Assuntos
Paralisia Bulbar Progressiva , Síndrome de Guillain-Barré , Síndrome de Miller Fisher , Doenças do Sistema Nervoso Periférico , Humanos , Feminino , Pessoa de Meia-Idade , Síndrome de Guillain-Barré/diagnóstico , Síndrome de Miller Fisher/diagnóstico , Síndrome de Miller Fisher/complicações , Imunoglobulina G , Paralisia Bulbar Progressiva/complicações , Debilidade Muscular , Cefaleia/diagnóstico , AutoanticorposRESUMO
We report a case of a 76-year-old man with Miller Fisher syndrome presenting with acute ophthalmoplegia and ataxia. Cerebrospinal fluid analysis showed normocytosis with an increased protein level. Serum anti-GQ1b IgG and anti-GT1a IgG antibodies were positive. Based on these results, the patient was diagnosed with Miller Fisher syndrome. He was treated with two courses of intravenous immunoglobulin, which improved his neurological symptoms. Brain perfusion single-photon emission computed tomography showed that cerebellar blood flow was decreased in the acute stage of the disease and improved after treatment. Although the prevailing view is that ataxia in Miller Fisher syndrome patients is of a peripheral origin, this case suggests that cerebellar hypoperfusion contributes to the development of ataxia in Miller Fisher syndrome.
Assuntos
Ataxia Cerebelar , Síndrome de Miller Fisher , Oftalmoplegia , Masculino , Humanos , Idoso , Síndrome de Miller Fisher/complicações , Síndrome de Miller Fisher/diagnóstico , Ataxia/diagnóstico , Oftalmoplegia/diagnóstico , Imunoglobulina GRESUMO
Ophthalmoplegia is the diagnostic hallmark of anti-GQ1b antibody syndrome. This study aimed to define the patterns of acute comitant strabismus in patients with anti-GQ1b antibody syndromes. We retrospectively analyzed the ocular motor findings in 84 patients with anti-GQ1b antibody-associated ophthalmoplegia during the acute phases. Of the 84 patients, 11 (13%) showed acute comitant strabismus. Compared to those without, patients with acute comitant strabismus frequently showed abnormal ocular motor findings that included gaze-evoked (n = 8), spontaneous (n = 4) and positional nystagmus (n = 4), saccadic hypermetria (n = 3), head-shaking nystagmus (n = 2), pulse-step mismatch (n = 1), and impaired visual cancellation of the vestibulo-ocular reflex (n = 1, p < 0.001). On the contrary, iridoplegia (p = 0.029) and ptosis (p = 0.001) were more commonly observed in patients with paralytic (incomitant) strabismus than in those with acute comitant strabismus. Comitant strabismus can manifest during the acute phase of anti-GQ1b antibody syndromes in association with other central ocular motor abnormalities. These findings implicate that the cerebellum and/or brainstem can be the primary target of the anti-GQ1b antibodies.
Assuntos
Síndrome de Miller Fisher , Oftalmoplegia , Estrabismo , Humanos , Estudos Retrospectivos , Síndrome de Miller Fisher/complicações , Síndrome de Miller Fisher/diagnóstico , Oftalmoplegia/etiologia , Tronco Encefálico , Estrabismo/etiologia , GangliosídeosRESUMO
Acute-onset ophthalmoplegia is a perplexing diagnosis in a young child. When the full-blown picture of ophthalmoplegia, ataxia, and areflexia is evident, the diagnosis of Miller-Fisher syndrome (MFS), a variant of Guillain-Barre syndrome (GBS), is almost certain. However, the same is not true for isolated external ophthalmoplegia as it is etiologically heterogeneous. Only anecdotal case reports of childhood-onset acute ophthalmoplegia exist in the literature. Adult series suggest that acute onset external ophthalmoplegia is often immune-mediated and is secondary to anti-GQ1b antibodies. We present a 30-month-old boy with acute-onset bilateral external ophthalmoplegia with highly elevated serum anti-GQ1b antibodies. The child had a rapid and complete recovery with intravenous immunoglobulin. A review of all published cases of childhood anti-GQ1b antibody syndrome was performed. The case highlights that anti-GQ1b antibody syndrome should be considered even in young children with acute-onset external ophthalmoplegia. The disease has a favorable prognosis. The majority improve on conservative management. Treatment with steroids or IVIG may be considered in some after weighing the risks and benefits.
Assuntos
Síndrome de Guillain-Barré , Síndrome de Miller Fisher , Oftalmoplegia , Adulto , Masculino , Criança , Humanos , Pré-Escolar , Gangliosídeos , Síndrome de Miller Fisher/complicações , Síndrome de Miller Fisher/diagnóstico , Oftalmoplegia/etiologia , Oftalmoplegia/complicações , Síndrome de Guillain-Barré/complicações , Ataxia/diagnóstico , Imunoglobulinas Intravenosas/uso terapêuticoRESUMO
Miller Fisher syndrome (MFS) is a variant of Guillain-Barré syndrome. Delayed facial palsy (DFP) is a symptom that occurs after other neurological symptoms begin to recover within four weeks from the onset of MFS. As there have been few detailed reports about DFP in MFS cases treated with additional immunotherapy, we investigated three cases of DFP in MFS treated with additional steroid therapies. The duration of facial palsy in our cases was 12-24 days. No severe adverse effects were observed. Although adverse side effects should be carefully monitored, additional steroid therapy might be a treatment option for MFS-DFP.
Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Paralisia Facial , Síndrome de Guillain-Barré , Síndrome de Miller Fisher , Humanos , Paralisia Facial/tratamento farmacológico , Paralisia Facial/etiologia , Síndrome de Guillain-Barré/diagnóstico , Síndrome de Miller Fisher/complicações , Síndrome de Miller Fisher/tratamento farmacológico , Síndrome de Miller Fisher/diagnóstico , Esteroides/uso terapêuticoRESUMO
This is a case report of a 48-year-old female with no medical conditions, with a one-day history of diplopia, mild headache, vertigo and generalized paraesthesia. The neurological examination revealed ophthalmoplegia, ataxia and areflexia leading to a diagnosis of Miller Fisher syndrome, a rare variant of Guillain-Barré syndrome. This highlights the importance of considering the rarer variants of Guillain-Barré syndrome in the differential diagnosis of patients who present with this triad.
Assuntos
Síndrome de Guillain-Barré , Síndrome de Miller Fisher , Oftalmoplegia , Diagnóstico Diferencial , Feminino , Síndrome de Guillain-Barré/diagnóstico , Cefaleia/diagnóstico , Cefaleia/etiologia , Humanos , Pessoa de Meia-Idade , Síndrome de Miller Fisher/complicações , Síndrome de Miller Fisher/diagnóstico , Síndrome de Miller Fisher/terapia , Oftalmoplegia/diagnóstico , Oftalmoplegia/etiologiaRESUMO
INTRODUCTION: Miller Fisher syndrome (MFS), regarded by many scholars as a variant of Guillain Barre syndrome (GBS), accounts for approximately 5% to 10% of GBS cases. The typical clinical manifestations of MFS are extraocular muscle paralysis, ataxia, and tendon reflex loss or disappearance. To date, intestinal obstruction has rarely been reported as the initial symptom. PATIENT CONCERNS: A 48-year-old woman presenting with abdominal pain and distention was diagnosed with paralytic ileus. There was no significant improvement in symptoms after symptomatic treatment. After that, the patient developed visual rotation, with limited binocular abduction and adduction, and ataxia. Anti-ganglioside testing revealed positive anti-ganglioside antibodies. DIAGNOSIS: The patient was diagnosed as MFS. INTERVENTIONS: The early stage is mainly symptomatic treatment of paralytic ileus. After MFS was diagnosed, the patient was given large amounts of immunoglobulin and hormone shock therapy. OUTCOMES: After 1 week, the symptoms of intestinal obstruction and MFS gradually improved. The patient was later discharged automatically for financial reasons. Six months after discharge, the patient was interviewed by telephone, and she had recovered. CONCLUSION: To date, intestinal obstruction has rarely been reported as the initial symptom. In case of inconsistencies between the imaging examinations and clinical symptoms, neuroelectrophysiology and cerebrospinal fluid puncture should be performed, striving for timely detection and treatment.
Assuntos
Síndrome de Guillain-Barré , Obstrução Intestinal , Pseudo-Obstrução Intestinal , Síndrome de Miller Fisher , Ataxia , Feminino , Humanos , Pseudo-Obstrução Intestinal/diagnóstico , Pseudo-Obstrução Intestinal/etiologia , Pseudo-Obstrução Intestinal/terapia , Pessoa de Meia-Idade , Síndrome de Miller Fisher/complicações , Síndrome de Miller Fisher/diagnóstico , Síndrome de Miller Fisher/terapiaRESUMO
Acute ataxia is a common neurologic presentation in the pediatric population that carries a broad differential diagnosis. The tempo of the presentation, distribution of the ataxia (focal or diffuse), examination findings, and paraclinical testing may be helpful in guiding diagnosis and management. Although Guillain-Barré syndrome (GBS) and its variant, Miller Fisher syndrome (MFS), are well defined, frequently encountered acute autoimmune neuropathies, the GBS/MFS spectrum have at least 12 different phenotypes with distinct neurologic features, 4 of which include ataxia. These lesser-known variants can be diagnosed clinically, in the absence of conclusive laboratory or neuroimaging data, and should always be considered in an acute presentation of ataxia. In this article, we present a previously healthy 8-year-old with acute onset ataxia with associated hyporeflexia that occurred after resolution of a presumed viral infection. We discuss our approach to ataxia, the patient's neurodiagnostic odyssey, and highlight the final diagnosis of acute ataxic neuropathy without ophthalmoplegia-a rare incomplete MFS subtype. Owing to timely recognition of the condition, the patient was treated appropriately and recovered fully.
Assuntos
Síndrome de Guillain-Barré , Síndrome de Miller Fisher , Oftalmoplegia , Ataxia/diagnóstico , Ataxia/etiologia , Raciocínio Clínico , Síndrome de Guillain-Barré/complicações , Síndrome de Guillain-Barré/diagnóstico , Humanos , Síndrome de Miller Fisher/complicações , Síndrome de Miller Fisher/diagnóstico , Oftalmoplegia/diagnósticoRESUMO
BACKGROUND: Neurologic impediments occur in only 0.1% of Mycoplasma pneumoniae infections. Although direct intracerebral infection can occur in these patients, autoimmune-mediated reactions secondary to molecular mimicry are the most common pathophysiology of such neurological complications. These complications include immune-mediated encephalitis, peripheral neuritis such as Guillain-Barré syndrome, and many others. Miller Fisher syndrome is a one of the variants of Guillain-Barré syndrome that has been rarely linked to Mycoplasma pneumoniae infection. It is a condition classically characterized by the triad of ophthalmoplegia, areflexia, and ataxia. Most patients with Miller Fisher syndrome will have positive anti-ganglioside GQ1b antibodies found in their serum, making this autoantibody a very useful serological confirmation parameter. We report a case of a Miller Fisher syndrome in a woman with Mycoplasma pneumoniae infection. To the best of the authors' knowledge, such cases have been only rarely described in literature. CASE PRESENTATION: A 35-year-old Chinese woman presented with sudden onset of double vision and ataxia 5 days after fever and mild flu symptoms. Her Mycoplasma pneumoniae antigen was positive with 1 over 2560 titer of total mycoplasma antibody and presence of immunoglobulin M antibody, suggesting acute infection, and her nerve conduction study revealed mild sensory axonal polyneuropathy with segmental demyelination. the Miller Fischer syndrome variant of Guillain-Barré syndrome secondary to Mycoplasma pneumonia was suspected and later confirmed by presence of serum anti-GQ1b autoantibody. She was treated with intravenous immunoglobulin 0.4 g/kg once daily for 5 days. CONCLUSIONS: The objective of this report is to share a case of an uncommon neurological complication of Mycoplasma pneumoniae infection, to increase the level of suspicion among clinicians that Miller Fischer syndrome can occur as an atypical presentation of an atypical pneumonia.
Assuntos
Síndrome de Miller Fisher , Oftalmoplegia , Pneumonia por Mycoplasma , Adulto , Feminino , Humanos , Imunoglobulinas Intravenosas , Síndrome de Miller Fisher/complicações , Síndrome de Miller Fisher/diagnóstico , Síndrome de Miller Fisher/tratamento farmacológico , Mycoplasma pneumoniae , Oftalmoplegia/etiologia , Pneumonia por Mycoplasma/complicações , Pneumonia por Mycoplasma/diagnóstico , Pneumonia por Mycoplasma/tratamento farmacológicoRESUMO
SARS-CoV-2 infections are increasingly associated with neurological complications, including immune-mediated neuropathies. Miller-Fisher syndrome is a rare variant of Guillain-Barré syndrome characterised by the triad of ataxia, ophthalmoplegia and areflexia. Here we present a case of Miller-Fisher syndrome following COVID-19 infection. The clinical presentation was a short history of a rapidly-progressive peripheral sensorimotor neuropathy with bulbar dysfunction and facial weakness following mild COVID infection. Examination revealed global areflexia and a broad-based ataxic gait. CSF analysis revealed albuminocytological dissociation and neurophysiological testing later supported the diagnosis. The patient required high flow nasal oxygen therapy for respiratory dysfunction in a level 2 care setting and received immunological treatment with intravenous immunoglobulins. We conclude that Miller-Fisher syndrome needs to be considered in patients presenting with new sensorimotor dysfunction following SARS-COV-2 infection. Early recognition is key given the propensity to cause life-threatening respiratory failure, and early administration of immunological treatment is associated with improved prognosis.
Assuntos
COVID-19 , Síndrome de Guillain-Barré , Síndrome de Miller Fisher , COVID-19/complicações , Síndrome de Guillain-Barré/diagnóstico , Síndrome de Guillain-Barré/etiologia , Humanos , Imunoglobulinas Intravenosas/uso terapêutico , Síndrome de Miller Fisher/complicações , Síndrome de Miller Fisher/diagnóstico , SARS-CoV-2RESUMO
PURPOSE: To evaluate the clinical features of pediatric patients with acute-onset, unilateral transient acquired blepharoptosis. METHODS: In this retrospective study, the clinical records of patients between April 2015 and June 2020 were reviewed for evaluation of demographic features, accompanying neurological and ophthalmologic manifestations, symptom duration, etiological cause, and imaging findings. Patients with congenital and acquired blepharoptosis with chronic etiologies were excluded. RESULTS: Sixteen pediatric patients (10 boys and 6 girls) with acquired acute-onset unilateral transient blepharoptosis were included in this study. The patients' mean age was 6.93 ± 3.16 years. The most commonly identified etiological cause was trauma in 7 patients (43.75%) and infection (para-infection) in 5 patients (31.25%). In addition, Miller Fisher syndrome, Horner syndrome secondary to neuroblastoma, acquired Brown's syndrome, and pseudotumor cerebri were identified as etiological causes in one patient each. Additional ocular findings accompanied blepharoptosis in 7 patients (58.33%). Blepharoptosis spontaneously resolved, without treatment, in all the patients, except those with Miller Fisher syndrome, neuroblastoma, and pseudotumor cerebri. None of the patients required surgical treatment and had ocular morbidities such as amblyopia. CONCLUSION: This study demonstrated that acute-onset unilateral transient blepharoptosis, which is rare in childhood, may regress without the need for surgical treatment in the pediatric population. However, serious pathologies that require treatment may present with blepharoptosis.
Assuntos
Blefaroptose , Síndrome de Miller Fisher , Neuroblastoma , Pseudotumor Cerebral , Masculino , Feminino , Criança , Humanos , Pré-Escolar , Blefaroptose/etiologia , Blefaroptose/cirurgia , Estudos Retrospectivos , Pseudotumor Cerebral/complicações , Síndrome de Miller Fisher/complicações , Neuroblastoma/complicaçõesRESUMO
BACKGROUND: Beyond the typical respiratory symptoms associated with novel coronavirus, increasing evidence has been reported of the neurological manifestations affecting both the central and peripheral nervous systems. CASE PRESENTATION: We observed a 30-year-old Persian woman developing acute motor sensory axonal neuropathy, a variant of Guillain-Barré syndrome that overlaps Miller Fisher syndrome, 30 days after confirmed coronavirus disease-2019 infection. Our case highlight the rare occurrence of Guillain-Barré syndrome overlapping with Miller Fisher during the coronavirus disease-2019 pandemic. These neurologic manifestations may occur because of an aberrant immune response to coronavirus disease-2019. CONCLUSIONS: The early recognition of Guillain-Barré syndrome symptoms is critical, given the associated severe motor disabilities that may seriously limit the quality of life of these patients. We may still have much to learn about the co-occurrence of Guillain-Barré syndrome and Miller Fisher to improve the quality of life of these patients requiring an accurate evaluation by neurologists.
Assuntos
COVID-19 , Síndrome de Guillain-Barré , Síndrome de Miller Fisher , Adulto , Feminino , Síndrome de Guillain-Barré/diagnóstico , Humanos , Síndrome de Miller Fisher/complicações , Síndrome de Miller Fisher/diagnóstico , Qualidade de Vida , SARS-CoV-2RESUMO
BACKGROUND: Pasteurella multocida can cause serious soft tissue infections and, less commonly, septic arthritis, osteomyelitis, and sepsis especially in immunocompromised hosts. P. multocida can cause meningitis or meningoencephalitis, occasionally with the formation of abscesses, but is rarely the cause of other neurological diseases. Miller Fisher Syndrome (MFS) is a parainfectious autoimmune disorder presenting with ophthalmoplegia, ataxia and areflexia. CASE PRESENTATION: We present the case of a 59-year-old immunocompetent patient who developed an atypical Miller Fisher/ Guillain-Barré-overlap-syndrome associated with a phlegmon caused by P. multocida, an associated bacteremia and sepsis leading to long intensive care treatment. Initial differential diagnosis was wound botulism. Patient was treated by antibiotics, wound cleansing with VAC pump and intravenous immunoglobulins. CONCLUSION: With this case we were able to show that a P. multocida infection can trigger atypical Miller Fisher/ Guillain-Barré-overlap-syndrome and that this is an important differential diagnosis of wound botulism.
Assuntos
Botulismo , Síndrome de Guillain-Barré , Síndrome de Miller Fisher , Pasteurella multocida , Sepse , Botulismo/complicações , Botulismo/diagnóstico , Síndrome de Guillain-Barré/complicações , Síndrome de Guillain-Barré/diagnóstico , Humanos , Unidades de Terapia Intensiva , Síndrome de Miller Fisher/complicações , Síndrome de Miller Fisher/diagnóstico , Sepse/complicaçõesRESUMO
Guillain-Barré syndrome (GBS) is the most common cause of acute neuropathy. It usually onset with a rapidly progressive ascending bilateral weakness with sensory disturbances, and patients may require intensive treatment and close monitoring as about 30% have a respiratory muscle weakness and about 10% have autonomic dysfunction. The diagnosis of GBS is based on clinical history and examination. Complementary examinations are performed to rule out a differential diagnosis and to secondarily confirm the diagnosis. GBS is usually preceded by an infectious event in ≈ 2/3 of cases. Infection leads to an immune response directed against carbohydrate antigens located on the infectious agent and the formation of anti-ganglioside antibodies. By molecular mimicry, these antibodies can target structurally similar carbohydrates found on host's nerves. Their binding results in nerve conduction failure or/and demyelination which can lead to axonal loss. Some anti-ganglioside antibodies are associated with particular variants of GBS: the Miller-Fisher syndrome, facial diplegia and paresthesias, the pharyngo-cervico-brachial variant, the paraparetic variant, and the Bickerstaff brainstem encephalitis. Their semiological differences might be explained by a distinct expression of gangliosides among nerves. The aim of this review is to present pathophysiological aspects and the diagnostic approach of GBS and its variants.